Yonhap Infomax NewsSep 22
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759
Celltrion Secures Regulatory Approval for Autoimmune Disease Biosimilar 'Avtozma' in Japan

Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.

Yonhap Infomax
Yonhap Infomax NewsMar 28, 2025
Yuhan Corporation's lung cancer drug Leclaza combination therapy receives approval as first-line treatment in Japan, marking significant milestone for Korean pharmaceutical industry
#YonhapInfomax #YuhanCorporation #Leclaza #LungCancerDrug #JapanApproval #FirstLineTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56147
Yuhan Corporation's Lung Cancer Drug Leclaza Combination Therapy Approved as First-Line Treatment in Japan

Yuhan Corporation's lung cancer drug Leclaza combination therapy receives approval as first-line treatment in Japan, marking significant milestone for Korean pharmaceutical industry

Yonhap Infomax